Important SOX17 downstream targets such as Notch signaling, BMPR2, estrogen receptor signaling, prostacyclin synthase and c-Met/HGF have been implicated in the endothelial dysfunction underlying Sox17's involvement in PAH. This evidence concerns the gene MET and pulmonary arterial hypertension.